Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TNK-LVO: Tenecteplase vs Alteplase Bridging Mechanical Thrombectomy for Acute Ischemic Stroke
NCT06658197Phase 3Recruiting
- Sponsor
- Xuanwu Hospital
- Start
- Dec 2025
- Primary completion
- Dec 2026
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tenecteplase in ischemic stroke (2 arms), sponsored by Xuanwu Hospital. Primary endpoint: Functional independence defined as modified Rankin Score <= 2 or no change from baseline at 90 days. Started Dec 2025; status: recruiting.
02
Drugs
tenecteplase
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT06658197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06658197.